Irina Rifkind

发表

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.

Jun Luo, E. Antonarakis, M. Carducci, 2020, European journal of cancer.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

C. Drake, Jun Luo, E. Antonarakis, 2018, The Lancet. Oncology.

A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.

Jun Luo, E. Antonarakis, M. Carducci, 2020, European urology.

Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).

Jun Luo, E. Antonarakis, M. Carducci, 2017 .